Physician profile
Jason V Hackett
NPI 1255327128
$3,665.02
in general payments reported to CMS, 2019-2025
24 companies · $670 in 2025
The $670 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $151 · 2021: $674 · 2022: $606 · 2023: $525 · 2024: $585 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,780.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $727.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $542.20 | 2019-2025 | |
| Lilly USA, LLC | $358.23 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $347.69 | 2019-2025 | Trintellix |
| Astrazeneca Pharmaceuticals Lp | $280.07 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Biohaven Pharmaceutical Holding Company Ltd. | $257.78 | 2022 | |
| Abbvie INC. | $151.18 | 2021-2025 | |
| Esperion Therapeutics, INC. | $145.94 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $133.37 | 2019 | |
| Exact Sciences Corporation | $117.56 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $94.61 | 2019-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $79.59 | 2019-2023 | Trelegy Ellipta, Bexsero |
| Biohaven Pharmaceuticals, INC. | $65.23 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.68 | 2021-2022 | |
| Astellas Pharma US INC | $47.59 | 2024 | Veozah |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $43.49 | 2022-2023 | Qelbree |
| Arbor Pharmaceuticals, INC. | $42.50 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $39.02 | 2022-2023 | Rexulti |
| Merck Sharp & Dohme LLC | $36.70 | 2019-2021 | |
| Genentech USA, INC. | $29.06 | 2022 | |
| Abbott Laboratories | $19.66 | 2021 | |
| Amarin Pharma, INC. | $16.52 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.35 | 2022 | |
| Currax Pharmaceuticals LLC | $14.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Hackett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.